SITC is pleased to announce the publication of the updated acute leukemia CPG, available in the Journal for ImmunoTherapy of Cancer.
This guideline includes updated expert guidance on immunotherapy treatment of B-ALL, AML, and BPDCN, including therapy selection, transplant considerations in the immunotherapy treatment landscape, toxicity management, treatment sequencing, and patient education and quality of life.
This is an updated to the previous acute leukemia guideline published in 2020.
The SITC Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer.
These CPGs offer a vital resource for the practicing oncology community. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure a fair, transparent and balanced process for creating the CPGs. Each CPG expert panel is comprised of a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States.
Acute Leukemia Guideline
Breast Cancer Guideline
Gynecologic Cancer Guideline
Gastrointestinal Cancer Guideline
Head and Neck Squamous Cell Carcinoma Guideline
Hepatocellular Carcinoma Guideline
ICI-related Adverse Events Guideline
IEC-related Adverse Events Guideline
Lung Cancer and Mesothelioma Guideline
Lymphoma Guideline
Melanoma Guideline
Multiple Myeloma Guideline
Nonmelanoma Skin Cancer Guideline
Prostate Carcinoma Guideline
Renal Cell Carcinoma Guideline
Urothelial Cancer Guideline